Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Abbvie Inc (ABBV)

Abbvie Inc (ABBV)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NYSE]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 335,210,304
  • Shares Outstanding, K 1,766,403
  • Annual Sales, $ 56,334 M
  • Annual Income, $ 4,278 M
  • EBIT $ 10,065 M
  • EBITDA $ 18,451 M
  • 60-Month Beta 0.48
  • Price/Sales 5.88
  • Price/Cash Flow 12.57
  • Price/Book 227.03

Options Overview Details

View History
  • Implied Volatility 28.16% ( unch)
  • Historical Volatility 17.62%
  • IV Percentile 80%
  • IV Rank 32.39%
  • IV High 51.27% on 04/08/25
  • IV Low 17.09% on 08/30/24
  • Put/Call Vol Ratio 0.52
  • Today's Volume 7,610
  • Volume Avg (30-Day) 12,405
  • Put/Call OI Ratio 0.65
  • Today's Open Interest 307,821
  • Open Int (30-Day) 324,316

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 27 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/25
See More
  • Average Estimate 2.87
  • Number of Estimates 1
  • High Estimate 2.87
  • Low Estimate 2.87
  • Prior Year 2.65
  • Growth Rate Est. (year over year) +8.30%

Price Performance

See More
Period Period Low Period High Performance
1-Month
181.73 +4.89%
on 06/27/25
193.59 -1.53%
on 06/12/25
+1.46 (+0.77%)
since 06/09/25
3-Month
164.96 +15.55%
on 04/10/25
198.98 -4.20%
on 05/02/25
+10.78 (+5.99%)
since 04/09/25
52-Week
163.81 +16.37%
on 11/19/24
218.66 -12.82%
on 03/10/25
+22.57 (+13.43%)
since 07/09/24

Most Recent Stories

More News
Wall Street ends mixed amid Trump's new tariff deadlines

Wall Street ended mixed a day after a broad sell-off in response to the Trump administration setting new tariffs on more than a dozen nations

WW : 39.35 (-0.51%)
BAC : 46.84 (-0.66%)
$SPX : 6,263.26 (+0.61%)
JPM : 283.16 (+0.13%)
ABBV : 190.62 (+0.45%)
$IUXX : 22,864.91 (+0.72%)
FSLR : 165.99 (+0.31%)
TSLA : 295.88 (-0.65%)
INTC : 23.44 (-0.64%)
EBS : 7.33 (+6.70%)
XOM : 113.80 (-0.34%)
$DOWI : 44,458.30 (+0.49%)
How Will Skyrizi and Rinvoq Sales Aid AbbVie's Upcoming Q2 Results?

AbbVie ABBV has successfully navigated the loss of exclusivity (LOE) for its flagship drug, Humira, by launching two newer immunology medicines, Skyrizi and Rinvoq. Investors will be most keen to know...

JNJ : 156.28 (+0.31%)
LLY : 786.92 (+1.19%)
ABBV : 190.62 (+0.45%)
Here's What to Expect From AbbVie's Next Earnings Report

AbbVie will release its second-quarter earnings later this month, and analysts anticipate a double-digit bottom-line growth.

XLV : 135.49 (+0.39%)
$SPX : 6,263.26 (+0.61%)
ABBV : 190.62 (+0.45%)
3 No-Brainer Stocks to Buy in July

LLY : 786.92 (+1.19%)
VRTX : 478.96 (+2.70%)
ABBV : 190.62 (+0.45%)
2 Dividend Stocks to Buy for Decades of Passive Income

ABT : 133.22 (-0.10%)
ABBV : 190.62 (+0.45%)
Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever

ENB : 43.79 (-0.93%)
ABBV : 190.62 (+0.45%)
O : 56.92 (-0.99%)
Here's How Lilly's Non-Obesity Drugs are Contributing to Sales Growth

While Eli Lilly’s LLY top-line continues to touch new sky highs thanks to its blockbuster GLP-1 medicines — Mounjaro (for type II diabetes) and Zepbound (for obesity) — which accounted for 48% of...

MRK : 83.71 (+2.88%)
LLY : 786.92 (+1.19%)
ABBV : 190.62 (+0.45%)
3 Giant Dividend Stocks to Buy to Shield Your Portfolio Now

These dividend stocks provide consistent income and long-term stability.

TGT : 102.43 (+0.41%)
T : 28.10 (-0.67%)
$SPX : 6,263.26 (+0.61%)
ABBV : 190.62 (+0.45%)
The Zacks Analyst Blog Highlights Alphabet, AbbVie and The Walt Disney

For Immediate ReleaseChicago, IL – July 2, 2025 – Zacks.com announces the list of stocks featured in the Analyst Blog. Every day the Zacks Equity Research analysts discuss the latest news and events...

GOOGL : 176.62 (+1.30%)
ABBV : 190.62 (+0.45%)
DIS : 120.61 (-0.99%)
Does J&J's Innovative Medicine Unit Hold the Key to Q2 Sales Growth?

Johnson & Johnson JNJ, under its Innovative Medicine segment, markets several multi-million-dollar drugs that cover a broad range of areas such as neuroscience, cardiovascular and metabolism, immunology,...

AZN : 70.82 (+1.14%)
JNJ : 156.28 (+0.31%)
ABBV : 190.62 (+0.45%)
AMGN : 296.52 (-0.16%)

Barchart Technical Opinion

The Barchart Opinion rating is a Hold. Short term, the outlook is Falling.

See More Share

Business Summary

AbbVie has become one of the top-most pharma companies after it acquired Allergan. The deal has transformed AbbVie's portfolio by lowering its dependence on Humira, its flagship product. AbbVie has one of the most popular cancer drugs in its portfolio, Imbruvica and its newest immunology drugs Skyrizi...

See More

Key Turning Points

3rd Resistance Point 194.47
2nd Resistance Point 192.78
1st Resistance Point 191.70
Last Price 190.62
1st Support Level 188.93
2nd Support Level 187.24
3rd Support Level 186.16

See More

52-Week High 218.66
Fibonacci 61.8% 197.71
Fibonacci 50% 191.24
Last Price 190.62
Fibonacci 38.2% 184.76
52-Week Low 163.81

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar